Please assess the completion status of the following clinical trial:

Trial Title: Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 seropositive~* Not on HIV-1 antiretroviral therapy nor planning to initiate antiretroviral therapy during the study period~* CD4 cell count \>250 cell/µL~* Not otherwise eligible for antiretroviral therapy according to Uganda national guidelines~* Detectable HIV-1 plasma viral load~* HSV-2 seropositive~* Not intending to move out of the area for the duration of study participation.~* Able to participate in the study at the Partners in Prevention site in Thika, Kenya~Exclusion Criteria:~* Known history of adverse reaction to acyclovir, valacyclovir, or famciclovir.~* Planned use of acyclovir, valacyclovir, or famciclovir~* Use of ganciclovir, foscarnet, or cidofovir~* Known medical history of seizures~* Serum creatinine \>1.5 mg/dL~* AST or ALT \>3 times upper limit of normal~* Hematocrit \<30 %~* Absolute neutrophil count \<1000~* Platelet count \<75,000~* History of thrombotic microangiopathy~* Any other condition which, in the opinion of the principal investigator, may compromise the ability to follow study procedures and complete the study~* Participation in another HIV therapeutics trial~* For women, pregnancy as confirmed by a urine pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- acyclovir (Type: ACTIVE_COMPARATOR): acyclovir 400 mg orally twice daily
- valacyclovir (Type: ACTIVE_COMPARATOR): valacyclovir 1.5 g orally twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).